• G Jeryczynski, M Antlanger, F Duca, C Binder-Rodriguez, T Reiter, I Simonitsch-Klupp, D Bonderman, R Kain, M-T Krauth, and H Agis.
• Division of Oncology, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
• ESMO Open. 2021 Apr 1; 6 (2): 100065.

BackgroundDaratumumab was the first monoclonal CD38 antibody with single-agent activity approved for the treatment of multiple myeloma. Moreover, daratumumab demonstrated high response rates in relapsed immunoglobulin light-chain (AL) amyloidosis.Patients And MethodsIn our single-center retrospective real-life case series, we analyzed the efficacy and safety of daratumumab as first-line treatment. Daratumumab was administered with low-dose dexamethasone alone or in combination with other multiple myeloma therapeutics RESULTS: Fourteen patients were eligible, including nine patients with cardiac stage IIIa or IIIb. Overall hematologic response rate was 100%, with 64.3% achieving complete response after a median of 16 cycles of treatment. Median time to hematologic response was 1.4 months. Organ response rates were 45.5% after a median of 4.0 months and 66.7% after a median of 10.0 months, for heart and kidney involvement, respectively. After a median follow-up of 20.5 months, two patients underwent successful autologous stem cell transplantation (ASCT), while another three patients were in preparation for ASCT. Three patients remained on daratumumab at the last follow-up. There were no unexpected toxicities and no grade III or IV adverse events, although more than half of our patients were in stage IIIa or IIIb.ConclusionDaratumumab proved to be highly effective in newly diagnosed AL amyloidosis with excellent hematologic and organ response rates, a remarkable safety profile, and good tolerability even in patients with advanced stage of disease.Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

14 keywords...

hide…